论文部分内容阅读
目的 :探讨司帕沙星 (SPFX)对感染性疾病的临床疗效和安全性。方法 :采用SPFX与洛美沙星 (LOM )随机对照治疗 70例细菌性感染病例 ,包括呼吸道感染 3 0例、泌尿道感染 3 0例和其他感染 10例。试验组用SPFX2 0 0～ 4 0 0mg/d ,qd ,po ,疗程 5～ 14d ;对照组用LOM 2 0 0～ 3 0 0mg/次 ,bid ,po,疗程 5～ 14d ,两组各完成 3 5例。 结果 :SPFX与LOM的临床治愈率分别是 80 0 0 %及 77 14 % ,细菌清除率分别是 96.97%及 10 0 .0 0 % ,不良反应发生率分别为 5 .71%及 2 .89% ,两组差异无显著性。结论 :本研究提示国产SPFX为安全、有效的广谱抗菌药物
Objective: To investigate the clinical efficacy and safety of sparfloxacin (SPFX) in infectious diseases. Methods: A total of 70 cases of bacterial infections were treated with SPFX and Lomefloxacin (LOM) randomly, including 30 cases of respiratory tract infection, 30 cases of urinary tract infection and 10 cases of other infections. The experimental group with SPFX2 0 0 ~ 400mg / d, qd, po, treatment for 5 ~ 14d; control group with LOM 200 ~ 300mg / time, bid, po, treatment of 5 ~ 14d, the two groups completed 3 5 cases. Results: The clinical cure rates of SPFX and LOM were 80 0% and 77 14% respectively. The bacterial clearance rates were 96.97% and 100.0% respectively. The incidence of adverse reactions were 5.71% and 2.89% , No significant difference between the two groups. Conclusion: This study suggests that domestic SPFX is a safe and effective broad-spectrum antibacterial drug